Ingevity Receives Five Analyst Ratings, BMO Raises Price Target

Summary

Ingevity Corporation (NYSE: NGVT) received an average ‘moderate buy’ rating from five analysts. Two analysts gave a ‘hold’ rating, while three issued ‘buy’ ratings. The 12-month average price target is $52.20. Recent reports include a downgrade from StockNews.com and an upgrade from BMO Capital Markets, which increased its price target to $65.00. Institutional investors hold 91.59% of the stock. Ingevity’s stock opened at $35.40, with a market capitalization of $1.29 billion and a negative net profit margin of 30.60%. The company reported earnings per share of $0.99 in the last quarter, exceeding expectations.Market Beat

Impact Analysis

This event is at the company level because it specifically pertains to Ingevity Corporation and involves analyst ratings and target price adjustments. The direct impact (first-order effect) is the potential influence on Ingevity’s stock price due to the analyst ratings and price target changes. The upgrade by BMO Capital Markets to ‘outperform’ with a higher target price may positively influence investor perception and demand for the stock, potentially leading to an increase in its price. Conversely, the downgrade by StockNews.com to ‘hold’ could temper investor enthusiasm, acting as a counterbalance. Second-order effects might include changes in trading activity among institutional investors who hold a significant portion of the stock (91.59%). For investors, this presents opportunities to buy or hold based on their view of the company’s future performance and the credibility they assign to the analysts’ ratings. Risks include the company’s negative net profit margin and potential volatility in stock price due to differing analyst opinions.Market Beat+ 2